InflaRx (IFRX) Interest Coverage Ratio (2016 - 2026)
InflaRx's (IFRX) quarterly Interest Coverage Ratio came in at 486.74 in Q1 2026, down 84.71% year-on-year from 3182.85 in Q1 2025, and down 16.07% quarter-over-quarter from 579.96 in Q4 2025.
InflaRx (IFRX) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
InflaRx has disclosed Interest Coverage Ratio across 11 years of filings, most recently posting 486.74 for Q1 2026.
- Interest Coverage Ratio for Q1 2026 came in at 486.74, down 84.71% year-over-year; the trailing twelve-month figure through Mar 2026 was 213.3 (up 560.61% YoY), and the FY2025 annual result was 0.0, up 52.08% from the prior year.
- Interest Coverage Ratio came in at 486.74 for Q1 2026 at InflaRx, down from 579.96 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3850.37 in Q2 2025 to a low of 260.38 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 1183.8 (2024), against an average of 1380.88.
- Peak annual rise in Interest Coverage Ratio reached 181361252269456.53% in 2023, while the deepest fall reached 119.87% in 2023.
- InflaRx's Interest Coverage Ratio stood at 1310.63 in 2022, then slumped by 119.87% to 260.38 in 2023, then soared by 554.65% to 1183.8 in 2024, then tumbled by 51.01% to 579.96 in 2025, then fell by 16.07% to 486.74 in 2026.
- The last three Interest Coverage Ratio figures came in at 486.74 (Q1 2026), 579.96 (Q4 2025), and 660.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -258.33 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 11.79 |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | 486.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 486.74 |
| Dec 31, 2025 | 579.96 |
| Sep 30, 2025 | 660.00 |
| Jun 30, 2025 | 3,850.37 |
| Mar 31, 2025 | 3,182.85 |
| Dec 31, 2024 | 1,183.80 |
| Sep 30, 2024 | 3,052.47 |
| Jun 30, 2024 | 1,763.25 |
| Mar 31, 2024 | 2,696.18 |
| Dec 31, 2023 | -260.38 |
| Sep 30, 2023 | 2,277.08 |
| Jun 30, 2023 | 1,950.94 |
| Mar 31, 2023 | 0.00 |
| Dec 31, 2022 | 1,310.63 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 136.77 |
| Mar 31, 2022 | 604.34 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 1,336.48 |
| Jun 30, 2021 | 4,584.32 |